Literature DB >> 16940352

Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+.

Elaine Huston1, Irene Gall, Thomas M Houslay, Miles D Houslay.   

Abstract

The unique N-terminal regions of PDE4 cAMP-specific phosphodiesterases confer interaction with distinct signalling and scaffolding proteins. The PDE4A1 isoform is unique in being entirely membrane associated. Its N-terminal region is formed from two helices separated by a mobile hinge, where helix-2 contains a TAPAS1 domain that inserts into the lipid bilayer in a Ca2+-triggered fashion. Here we show that helix-1 is important for intracellular targeting of PDE4A1 in living cells, facilitating membrane association, targeting to the trans-Golgi stack and conferring Ca2+-stimulated intracellular redistribution in a manner that is dependent on the phospholipase-D-mediated generation of phosphatidic acid. The LxDFF motif within helix-1 is pivotal to this, where Leu4-Phe6-Phe7 forms a compact hydrophobic pocket on one side of helix-1 whereas Asp5, located on the opposite face of helix-1, provides the Ca2+-regulation site. Mutation of Asp5 to Ala or the release of Ca2+ from intracellular stores de-restricts trans-Golgi localisation of PDE4A1 allowing it to redistribute in cells in a phosphatidic-acid-dependent manner. This study provides the first evidence for Ca2+-triggered relocalisation of a cAMP phosphodiesterase and indicates a potential means for allowing cross-talk between the cAMP, phospholipase D and Ca2+-signalling pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940352     DOI: 10.1242/jcs.03106

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  14 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

4.  State-dependent disruption of short-term facilitation due to overexpression of the apPDE4 supershort form in Aplysia.

Authors:  Deok-Jin Jang; Jin-A Lee; Yeon-Su Chae; Bong-Kiun Kaang
Journal:  Mol Cells       Date:  2010-12-30       Impact factor: 5.034

5.  Comparative Characterization of Phosphatidic Acid Sensors and Their Localization during Frustrated Phagocytosis.

Authors:  Nawal Kassas; Emeline Tanguy; Tamou Thahouly; Laetitia Fouillen; Dimitri Heintz; Sylvette Chasserot-Golaz; Marie-France Bader; Nancy J Grant; Nicolas Vitale
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

6.  The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s).

Authors:  Moses Xie; Brigitte Blackman; Colleen Scheitrum; Delphine Mika; Elise Blanchard; Tao Lei; Marco Conti; Wito Richter
Journal:  Biochem J       Date:  2014-05-01       Impact factor: 3.857

7.  An evolutionary analysis of cAMP-specific Phosphodiesterase 4 alternative splicing.

Authors:  Keven R Johnson; Jessie Nicodemus-Johnson; Robert S Danziger
Journal:  BMC Evol Biol       Date:  2010-08-11       Impact factor: 3.260

8.  Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Authors:  Kirsty F Mackenzie; Emma C Topping; Bozena Bugaj-Gaweda; Chengjun Deng; York-Fong Cheung; Aileen E Olsen; Cecil R Stockard; Lisa High Mitchell; George S Baillie; William E Grizzle; Michael De Vivo; Miles D Houslay; Daguang Wang; Graeme B Bolger
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

9.  Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Authors:  M Campos-Toimil; T Keravis; F Orallo; K Takeda; C Lugnier
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

Review 10.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.